返回 
加入收藏
卡瑞利珠单抗联合化疗用于我国宫颈癌患者的药物经济学评价
x
请在关注微信后，向客服人员索取文件
| 篇名： | 卡瑞利珠单抗联合化疗用于我国宫颈癌患者的药物经济学评价 |
| TITLE： | Pharmacoeconomic evaluation of camrelizumab combined with chemotherapy in the treatment of cervical cancer in China |
| 摘要： | 目的 对卡瑞利珠单抗联合化疗用于我国宫颈癌患者的经济性进行评价。方法从中国卫生体系角度出发，基于卡瑞利珠单抗联合化疗治疗宫颈癌的文献资料构建Markov模型，其中不良反应发生情况通过Meta分析获得。设置研究时限为10年，循环周期为3周。成本包括药品成本、不良反应治疗成本等直接成本，效用值参考现有研究，转移概率基于文献数据计算，贴现率为5%，意愿支付（WTP）阈值采用3倍我国2024年人均国内生产总值（GDP）即287247元/质量调整生命年（QALY），比较卡瑞利珠单抗联合或不联合化疗的经济性，并通过单因素敏感性分析和蒙特卡罗模拟评估参数波动对结果的影响。结果与单用卡瑞利珠单抗方案比较，卡瑞利珠单抗联合化疗方案的增量成本-效果比为181507.58元/QALY，小于本研究设定的WTP阈值。单因素分析结果显示，两组无进展生存状态到死亡的转移概率对结果的影响较大；概率敏感性分析结果表明，以3倍我国2024年人均GDP为WTP阈值时，卡瑞利珠单抗联合化疗方案具有经济性的概率为91.8%。结论从中国卫生体系角度出发，与单用卡瑞利珠单抗方案比较，当以3倍我国2024年人均GDP为WTP阈值时，卡瑞利珠单抗联合化疗用于我国宫颈癌患者具有经济性。 |
| ABSTRACT： | OBJECTIVE To perform a pharmacoeconomic evaluation of camrelizumab combined with chemotherapy in the treatment of cervical cancer in China. METHODS From the perspective of China’s healthcare system， a Markov model was constructed based on literature data regarding the treatment of cervical cancer with camrelizumab combined with chemotherapy， where the incidence of adverse reactions was obtained through a meta-analysis. The model was run over a 10-year time horizon with a 3-week cycle length. Costs included direct costs （e.g. drug cost， adverse event treatment cost）. Utility values were derived from existing studies， and transition probabilities were calculated using literature data， with a discount rate of 5%； the willingness-to-pay （WTP） threshold was set at 3 times China’s 2024 per capita gross domestic product （GDP）， i.e. 287 247 yuan/quality-adjusted life year（QALY）. Cost-effectiveness was compared between camrelizumab combined with chemotherapy and monotherapy. One-way sensitivity analysis and Monte Carlo simulation were used to evaluate the impact of parameter variations on results. RESULTS Compared with camrelizumab monotherapy， the incremental cost-effectiveness ratio （ICER） of camrelizumab combined with chemotherapy was 181 507.58 yuan/QALY， below the predefined WTP threshold. One-way sensitivity analysis showed that the outcomes were largely affected by the progression-free survival-to-death transition probabilities in both groups. Probabilistic sensitivity analysis indicated a 91.8% probability of camrelizumab combined with chemotherapy being cost-effective at a WTP threshold of 3 times China’s 2024 per capita GDP. CONCLUSIONS From China’s healthcare system perspective， camrelizumab combined with chemotherapy is cost-effective for cervical cancer in China， compared with monotherapy， when using 3 times China’s 2024 per capita GDP as the WTP threshold. |
| 期刊： | 2025年第36卷第14期 |
| 作者： | 杨颂恬；严波 |
| AUTHORS： | YANG Songtian，YAN Bo |
| 关键字： | 卡瑞利珠单抗；宫颈癌；药物经济学评价 |
| KEYWORDS： | camrelizumab； cervical cancer； pharmacoeconomic evaluation |
| 阅读数： | 7 次 |
| 本月下载数： | 0 次 |
* 注：未经本站明确许可，任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作！
